Podcast: Efficacy of Vedolizumab in Patients with Moderately to Severely Active Crohn’s disease

Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab  in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed. Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective

Read more

In Treating Crohn’s Disease, Earlier is Better

Patients receiving medical therapies when they have more complicated stages of Crohn’s disease (CD) are more likely to require surgery, researchers report in the March issue of Clinical Gastroenterology and Hepatology. The disease is most-effectively treated by drugs at its early, inflammatory stages. Patients have a 40%–71% risk for requiring

Read more

Can a microRNA Control Inflammation in Patients With Ulcerative Colitis?

Loss of a non-coding RNA that regulates inflammation could contribute to development of ulcerative colitis (UC) in children, according to the October issue of Gastroenterology. UC and Crohn’s disease are chronic inflammatory bowel diseases that affect adults and children. These diseases are complex, and caused by combinations of genetic and

Read more
  • Is Gluten the Culprit in Non-Celiac Gluten Sensitivity?

Is Gluten the Culprit in Non-Celiac Gluten Sensitivity?

Rapidly fermented poorly absorbed short-chain carbohydrates, rather than gluten or other wheat proteins, might cause gastrointestinal symptoms in people who do not have celiac disease but feel better on gluten-free diets, according to the August issue of Gastroenterology. Individuals with non-celiac gluten sensitivity (NCGS), do not have celiac disease (based on

Read more

Are All Patients With IBD at Increased Risk for Colorectal Cancer?

Although inflammatory bowel disease (IBD) increases risk for colorectal cancer (CRC), the risk is only substantial among patients with long-term, extensive colitis. Furthermore, CRC risk is reduced by thiopurine therapy, according to the July issue of Gastroenterology. Laurent Beaugerie et al. collected data from 19,486 patients with IBD (60% with

Read more